PromarkerD patent granted in Hong Kong

The prevalence of diabetes is increasing worldwide, particularly in Asian countries, which contribute 55% of the global population living with diabetes. Hong Kong is home to approximately 686,000 adults with diabetes.

Patent joins those already granted for the USA, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore, India and Japan.

Proteomics International Managing Director Dr Richard Lipscombe said it was important to secure a patent for Hong Kong, which complements the Company’s patent protection for the region. “Proteomics International already has patent protection in China and the granting of the Hong Kong patent, which includes pre-diabetes expands that protection. Hong Kong is an important gateway market and there is the potential for PromarkerD testing to be introduced there prior to entering the much larger China market.

ASX Release